---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009686"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:13:39.199812+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar reports Q4/FY2023 net loss of $1.8M/$8.4M; MNPR-101 Phase 1 dosimetry trial to start

## Summary
- Cash, equivalents and short-term investments $7.3M at Dec. 31, 2023; plus $3.2M from Q1 2024 ATM; runway through June 30, 2025.
- Net loss Q4 2023: $1.8M ($0.12/shr) vs $2.9M ($0.22/shr) in Q4 2022; FY 2023: $8.4M ($0.61/shr) vs $10.5M ($0.83/shr) in FY 2022.
- R&D expenses fell to $1.0M in Q4 2023 ($2.1M Q4 2022) and $5.6M for FY 2023 ($7.6M FY 2022), driven by Validive cost reductions.
- MNPR-101-Zr Phase 1 dosimetry trial cleared by HREC in Australia; lead investigator Professor Rodney Hicks; enrollment imminent.
- Preclinical data: MNPR-101-Ac-225 caused near-complete tumor elimination in triple-negative breast xenograft model after single dose.

## SEC filing metadata
- accession: 0001437749-24-009686
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/0001437749-24-009686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/mnpr20240325_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009686
- JSON: https://secwatch.observer/filing/0001437749-24-009686.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009686.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share.
  - Period: fourth quarter and full year ended December 31, 2023
  - Net income: Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share
  - Result: reported results
  source text: Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/0001437749-24-009686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.